658 related articles for article (PubMed ID: 34472586)
1. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.
Ginsberg HN; Packard CJ; Chapman MJ; Borén J; Aguilar-Salinas CA; Averna M; Ference BA; Gaudet D; Hegele RA; Kersten S; Lewis GF; Lichtenstein AH; Moulin P; Nordestgaard BG; Remaley AT; Staels B; Stroes ESG; Taskinen MR; Tokgözoğlu LS; Tybjaerg-Hansen A; Stock JK; Catapano AL
Eur Heart J; 2021 Dec; 42(47):4791-4806. PubMed ID: 34472586
[TBL] [Abstract][Full Text] [Related]
2. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.
Toth PP
Vasc Health Risk Manag; 2016; 12():171-83. PubMed ID: 27226718
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study.
Björnson E; Adiels M; Taskinen MR; Burgess S; Rawshani A; Borén J; Packard CJ
Eur Heart J; 2023 Oct; 44(39):4186-4195. PubMed ID: 37358553
[TBL] [Abstract][Full Text] [Related]
4. Triglyceride-rich lipoproteins and cardiovascular diseases.
Xu D; Xie L; Cheng C; Xue F; Sun C
Front Endocrinol (Lausanne); 2024; 15():1409653. PubMed ID: 38883601
[TBL] [Abstract][Full Text] [Related]
5. Postprandial lipoproteins and the molecular regulation of vascular homeostasis.
Botham KM; Wheeler-Jones CP
Prog Lipid Res; 2013 Oct; 52(4):446-64. PubMed ID: 23774609
[TBL] [Abstract][Full Text] [Related]
6. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease.
Duran EK; Pradhan AD
Clin Chem; 2021 Jan; 67(1):183-196. PubMed ID: 33409533
[TBL] [Abstract][Full Text] [Related]
7. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
8. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: current status and treatments.
Reyes-Soffer G
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):85-89. PubMed ID: 33481422
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease.
Ganda OP
Curr Opin Lipidol; 2023 Jun; 34(3):105-113. PubMed ID: 36924359
[TBL] [Abstract][Full Text] [Related]
10. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
[TBL] [Abstract][Full Text] [Related]
11. Remnant lipoproteins and atherosclerotic cardiovascular disease.
Tada H; Nohara A; Inazu A; Mabuchi H; Kawashiri MA
Clin Chim Acta; 2019 Mar; 490():1-5. PubMed ID: 30553862
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
13. Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease.
Packard CJ
Curr Atheroscler Rep; 2022 Mar; 24(3):133-142. PubMed ID: 35175548
[TBL] [Abstract][Full Text] [Related]
14. CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.
Shimizu-Albergine M; Basu D; Kanter JE; Kramer F; Kothari V; Barnhart S; Thornock C; Mullick AE; Clouet-Foraison N; Vaisar T; Heinecke JW; Hegele RA; Goldberg IJ; Bornfeldt KE
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34491909
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
Nordestgaard BG
Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
[TBL] [Abstract][Full Text] [Related]
16. New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
Rosenson RS; Shaik A; Song W
J Am Coll Cardiol; 2021 Nov; 78(18):1817-1830. PubMed ID: 34711341
[TBL] [Abstract][Full Text] [Related]
17. Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations.
Lütjohann D; Klör HU; Stellaard F
Nutrients; 2023 May; 15(9):. PubMed ID: 37432317
[TBL] [Abstract][Full Text] [Related]
18. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
19. Triglycerides: How to Manage Patients with Elevated Triglycerides and When to Refer?
Bazarbashi N; Miller M
Med Clin North Am; 2022 Mar; 106(2):299-312. PubMed ID: 35227432
[TBL] [Abstract][Full Text] [Related]
20. Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease.
Heo JH; Jo SH
J Korean Med Sci; 2023 Sep; 38(38):e295. PubMed ID: 37750369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
